Continuous and Daily Oral Immunotherapy for Peanut Allergy: Results from a 2-Year Open-Label Follow-On Study (vol 9, pg 1879, 2021) von Vickery, BP, Vereda, A, Nilsson, C, du Toit, G, Shref, WG, Burks, AW, Jones, SM, Fernandez-Rivas, M, Blumchen, K, Hourihane, JO, Beyer, K, Anagnostou, A, Assa'ad, AH, Ben-Shoshan, M, Bird, JA, Carr, TF, Ciaccio, W, Casale, TB, Chong, HJ, Ciaccio, CE, Dorsey, MJ, Fineman, SM, Fritz, SB, Greiner, AN, Greos, LS, Hampel, FC, Ibanez, MD, Jeong, DK, Johnston, DT, Kachru, R, Kim, EH, Lanser, BJ, Leonard, SA, Maier, MC, Mans, LE, Muraro, A, Ohayon, JA, Elberink, JNGO, Petroni, DH, Pongracic, JA, Portnoy, JM, Rachid, R, Rupp, NT, Sanders, GM, Sharma, HP, Sharma, V, Sher, ER, Sher, L, Sindher, SB, Siri, D, Spergel, JM, Sprikkelman, AB, Sussman, GL, Tsoumani, M, Varshney, P, Vitalpur, G, Wang, JL, Yang, WLH, Zubeldia, JM, Smith, A, Ryan, R, Adelman, DC

Volltext

Continuous and Daily Oral Immunotherapy for Peanut Allergy: Results from a 2-Year Open-Label Follow-On Study (vol 9, pg 1879, 2021) von Vickery, BP, Vereda, A, Nilsson, C, du, Toit G, Shref, WG, Burks, AW, Jones, SM, Fernandez-Rivas, M, Blumchen, K, Hourihane, JO

Volltext